Xylem IncXYL
Price$101.27Intrinsic value$136.2435% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $9.1B+6.6% YoYTTM through 30 Jun 2026
Net Income $1B+14.4% YoYTTM through 30 Jun 2026
Free Cash Flow $960MTTM through 30 Jun 2026

Margins

Current
Gross Margin39.2%
EBITDA Margin20.7%
Operating Margin14.5%
Net Margin11.2%

Returns

9.8%ROE
5.9%ROA
8.4%ROIC

Balance Sheet Health

Debt / Equity0.28x
Current Ratio1.61x
Net Debt$1.7B
Cash & Equivalents$1.3B

Quality Metrics

Altman Z-Score3.48
Piotroski F-Score8 / 9
FCF Margin10.5%
Rule of 4011.3
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $9B
Diluted EPS$4.20TTM
'19'20'21'22'23'24'25
FY2025: $3.92

Dividend

$0.86Per share, FY20260.80%Yield-5.1%5-yr growth

Capital Allocation

R&D Spend$227M
Capex Intensity3.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.